Compare Smith & Nephew plc (SNN) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Weibo Corp — how do they compare? Smith & Nephew plc trades at $27.13 (market cap $11.10B), while Weibo Corp trades at $6.55 (market cap $1.56B). The key difference: Smith & Nephew plc is far larger — about 7.1× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (9.47%). Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and Weibo Corp for 102 Days on average.
| SNN | WB | |
|---|---|---|
Market Cap | $11.10B | $1.56B |
Volume | 1,051,703 | 812,503 |
Sector | Health | Media |
52-Week High | $37.17 | $12.37 |
52-Week Low | $26.42 | $6.33 |
Typical Hold Time | 120 Days | 102 Days |
Enterprise Value | $14.13B | $786.69M |
Dividend Yield | 2.95% | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Weibo (WB) trades at $6.55, up 1.08% on the day, with a bearish technical signal. The stock is fundamentally attractive with a low P/E of 5.32 and P/B of 0.4, while profitability remains solid with a net income margin of 17.78%. Recent Q2 2026 earnings beat expectations, though revenue growth is modest. Cash flow trends show volatility, with a significant net outflow in 2024.
The outlook is mixed; deep-value metrics and strong cash generation offer upside, but declining user metrics and advertising headwinds pose risks. Analyst consensus is divided, leaning slightly toward Hold. The stock presents a value opportunity for patient investors, contingent on stabilizing user engagement and advertising demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
